Daxor Corporation (NASDAQ: DXR) shares picked up ground Thursday.
The Oak Ridge, Tennessee-based company, claiming to be the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor’s Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment.
The research, titled, “Patient Sex Impacts Volume Phenotypes and Hemodynamics in Chronic Heart Failure,” analyzed data from 255 heart failure patients across three major medical institutions: Mayo Clinic in Rochester, Duke University Medical Center, and Baptist Hospital in Memphis. Each patient underwent both BVA and pressure assessment.
The study revealed several critical findings:
• Commonly used hemodynamic pressure measures are inaccurate surrogates compared to direct blood volume analysis with Daxor BVA.
• BVA enables more accurate diagnosis of true anemia which is a key guideline target of care.
• Sex-specific volume differences as illuminated by BVA require individualized treatment approaches.
“We developed and market,” claims this morning’s news release, “the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.”
DXR shares gathered 17 cents, or 2.4%, to $7.22.
